Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection

Eun-Hee Cho

doi:10.4093/dmj.2022.0372

Articles

Page Path: HOME > Diabetes Metab J > Volume 46(6); 2022 > Article

Editorial Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection: Eun-Hee Cho; Diabetes & Metabolism Journal 2022;46(6):827-828.
DOI: https://doi.org/10.4093/dmj.2022.0372
Published online: November 24, 2022

7,035 Views
188 Download
9 Web of Science
8 Crossref
10 Scopus

Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea

Corresponding author: Eun-Hee Cho

Department of Internal Medicine, Kangwon National University School of Medicine, 1 Gangwondaehak-gil, Chuncheon 24341, Korea E-mail: ehcho@kangwon.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

Full Article

Download PDF

NOTES
REFERENCES
About this article

Diabetes is a heterogeneous chronic disease which affects 16.7% among the Korean adult aged 30 years and older and more than half of people with diabetes (55.1%) in Korea are obese (body mass index ≥25.0 kg/m²) in 2020 [1] suggesting the insulin resistance as a core mechanism to develop type 2 diabetes mellitus (T2DM).

Among Korean adults with T2DM, new antidiabetic medications such as dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors had dramatically increased from 2002 to 2018; however, the use of insulin and thiazolidinediones (TZDs) remained low and stable from 2002 to 2018 [1].

TZDs are peroxisome proliferator-activated receptor γ (PPARγ) agonists, which improve insulin sensitivity in skeletal muscle and reduce hepatic glucose production in patients with T2DM [2]. They have long glycemic durability and more weight gain, more edema and less hypoglycemia than metformin or glyburide [3].

Currently, pioglitazone, now generically affordable, and lobeglitazone are available for T2DM in Korea. Lobeglitazone (Chong Kun Dang Pharmaceutical Corporation, Seoul, Korea) was a novel PPARγ agonist, which was developed and approved in Korea in 2013. Introduction of a p-methoxyphenoxy group at the 4-position of the pyrimidine moiety, which was based on a modification of the rosiglitazone structure induces 12 times higher affinity to PPARγ compared to rosiglitazone and pioglitazone [4] to meet the demands for a more effective and safer TZD with lower dose.

Lobeglitazone 0.5 mg showed a favorable glycosylated hemoglobin (HbA1c) reduction (–0.44% vs. 0.16% in the placebo group, P<0.0001) and safety profile over 24 weeks as a monotherapy [5]. In add-on study to metformin with lobeglitazone, it showed similar HbA1c reduction in the pioglitazone to metformin combination group [6] and non-inferior to sitaglitpin add-on therapy [7]. In a Korean real-world study, lobeglitazone showed good glycemic-lowering effect, long-term durability of glycemic control and long-term safety profile with no cases of bladder cancer, one case of CHF, and 1.17% fracture rate of all patients [8].

The American Diabetes Association (ADA) 2022 guidelines [9] recommends that first-line therapy depends on comorbidities, patient-centered treatment factors and a GLP-1RA or a SGLT2 inhibitor is recommended as an appropriate initial therapy for individuals with T2DM with comorbidity such as atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and/or chronic kidney disease (CKD).

For those without compelling comorbidity indication, second-line options may be selected depending on if the highest priority is minimizing hypoglycemia, weight gain, or cost and access. In the current guidelines, TZDs may be considered as second-line agents if the priority is to minimize cost and access or risk of hypoglycemia. However, TZDs are the only class of glucose-lowering agents that primarily target the insulin resistance and have benefit of reducing the risk of ASCVD and improving nonalcoholic steato-hepatitis and β-cell function [10-12]. Considering the adverse effects as edema, HF, and weight gain, SGLT2 inhibitors or GLP-1RAs combined with TZDs could be a better option to improve insulin resistance and to target different pathophysiology thereby, minimizing the TZDs-related side effects.

The PROactive trial showed that pioglitazone decreased the ‘main secondary endpoint’ of all-cause mortality, non-fatal myocardial infarction, and stroke compared to placebo in 5,238 patients with T2DM with prior cardiovascular (CV) event, but there was no significant difference in the primary composite endpoint including additional acute coronary syndrome, endovascular or surgical intervention in the coronary or leg arteries, and amputation above the ankle [10]. As for lobeglitazone, additional clinical studies are expected to provide further evidence of the beneficial CV effects of lobeglitazone because the choice within same TZDs class is to be based on whether there was proven beneficial CV outcome trial. Regarding the limitation of current ADA and Korean guidelines focusing only on the co-morbidities such as ASCVD, HF, or CKD, clinician should consider the aspect of pathophysiology of T2DM as insulin resistance together which concur with obesity when to choose the anti-diabetic agents.

NOTES

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Bae JH, Han KD, Ko SH, Yang YS, Choi JH, Choi KM, et al. Diabetes fact sheet in Korea 2021. Diabetes Metab J 2022;46:417-26.Article PubMed PMC PDF
2. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.Article PubMed
3. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.Article PubMed
4. Lee MA, Tan L, Yang H, Im YG, Im YJ. Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs. Sci Rep 2017;7:16837.Article PubMed PMC PDF
5. Kim SG, Kim DM, Woo JT, Jang HC, Chung CH, Ko KS, et al. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLoS One 2014;9:e92843.Article PubMed PMC
6. Jin SM, Park CY, Cho YM, Ku BJ, Ahn CW, Cha BS, et al. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab 2015;17:599-602.PubMed PMC PDF
7. Kim SG, Kim KJ, Yoon KH, Chun SW, Park KS, Choi KM, et al. Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24weeks. Diabetes Obes Metab 2020;22:1869-73.Article PubMed PDF
8. Kim BY, Kwon HS, Kim SK, Noh JH, Park CY, Park HK, et al. A real-world study of long-term safety and efficacy of lobeglitazone in Korean patients with type 2 diabetes mellitus. Diabetes Metab J 2022;46:855-65.Article PubMed PMC PDF
9. American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, et al. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care 2022;45(Suppl 1):S125-43.
10. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, MassiBenedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.Article PubMed
11. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-31.Article PubMed PMC
12. DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res 2019;16:133-43.Article PubMed PDF

Figure & Data

References

Citations

Citations to this article as recorded by

Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
Diabetes, Obesity and Metabolism.2026; 28(3): 1764. CrossRef
Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics
Lilian Anagnostopoulou, Nikolaos Ktenopoulos, Anastasios Apostolos, Christos Fragoulis, Panayotis Vlachakis, Paschalis Karakasis, Marios Sagris, Nikias Milaras, Maria Drakopoulou, Andreas Synetos, Ioannis Kyriazis, Ioannis Ioannidis, Costas Tsioufis, Kons
Diabetes/Metabolism Research and Reviews.2026;[Epub] CrossRef
Cardiovascular outcomes with thiazolidinediones and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus undergoing peripheral artery revascularization
Ji Woong Roh, Jimin Jeon, Joonsang Yoo, Minyoul Baik, Seok-Jae Heo, Deok-Kyu Cho, Jinkwon Kim
Diabetes Research and Clinical Practice.2026; 236: 113281. CrossRef
Identification of Novel Organo-Se BTSA-Based Derivatives as Potent, Reversible, and Selective PPARγ Covalent Modulators for Antidiabetic Drug Discovery
Fangyuan Chen, Qingmei Liu, Lei Ma, Cuishi Yan, Haiman Zhang, Zhi Zhou, Wei Yi
Journal of Medicinal Chemistry.2025; 68(1): 819. CrossRef
Diabetes: a review of its pathophysiology, and advanced methods of mitigation
Sarika Gupta, Nitin Sharma, Sandeep Arora, Saurabh Verma
Current Medical Research and Opinion.2024; 40(5): 773. CrossRef
A Green Approach: Optimization of the UPLC Method Using DoE Software for Concurrent Quantification of Pioglitazone and Dapagliflozin in a SNEDDS Formulation for the Treatment of Diabetes
Ehab M. Elzayat, Abdelrahman Y. Sherif, Mohamed W. Attwa, Mohammad A. Altamimi
ACS Omega.2024; 9(45): 45011. CrossRef
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
Cardiovascular Diabetology.2023;[Epub] CrossRef
Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes
Julita Tokarek, Emilian Budny, Maciej Saar, Kamila Stańczak, Ewa Wojtanowska, Ewelina Młynarska, Jacek Rysz, Beata Franczyk
Biomedicines.2023; 11(10): 2611. CrossRef

PubReader
ePub Link

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection

Diabetes Metab J. 2022;46(6):827-828. Published online November 24, 2022

DOI: https://doi.org/10.4093/dmj.2022.0372

XML Download

Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection

About this article

Cho EH. Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection. Diabetes Metab J. 2022;46(6):827-828.

DOI: https://doi.org/10.4093/dmj.2022.0372.

Download citation ↓